Eli Lilly Aktie

748,40 EUR -13,70 EUR -1,80 %

27.12.2024

FSE

782,51 USD -1,40 USD -0,18 %

nachbörslich27.12.2024

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.713,10 Mrd. EUR

KGV100,48Div. Rendite0,78%

WKN858560

ISINUS5324571083

SymbolLLY

Eli Lilly Aktien News

Sortieren:Datum Meistgelesen

27.04.23PR NewswireLilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2

24.04.23PR NewswireLilly to Divest BAQSIMI to Amphastar

17.04.23PR NewswireLilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities

13.04.23PR NewswireU.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab

13.04.23PR NewswireLilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement

14.03.23PR NewswireLilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting

08.03.23PR NewswireLilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease

08.03.23PR NewswireUS FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes

06.03.23PR NewswireIntensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according t...

03.03.23PR NewswireU.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

01.03.23PR NewswireLilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month

21.02.23PR NewswireLilly to Participate in Cowen's 43rd Annual Health Care Conference

13.02.23PR NewswireLilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh

07.02.23PR NewswireLilly to Participate in SVB Securities Global Biopharma Conference

03.02.23PR NewswireLilly to Participate in Guggenheim Oncology Conference

27.01.23PR NewswireU.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Line...

26.01.23PR NewswireLilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity

24.01.23PR NewswireLilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park

20.01.23PR NewswireUS FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease

20.01.23PR NewswireU.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab

19.01.23PR NewswireLilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement

04.01.23PR NewswireLilly to Participate in the J.P. Morgan Healthcare Conference

14.12.22PR NewswireLilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa

13.12.22PR NewswireLilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines

13.12.22MyDividendsEli Lilly erhöht die Dividende

12.12.22PR NewswireLoxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting

12.12.22PR NewswireLilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend

07.12.22PR NewswirePhase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes

06.12.22PR NewswireLilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology

01.12.22PR NewswireLilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

01.12.22PR NewswireLilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease

30.11.22PR NewswireLilly and Akouos Announce Expiration of Akouos Tender Offer

30.11.22RSSForm SC TO-T/A 59478

29.11.22PR NewswireLilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement

28.11.22RSSForm SC TO-T/A 59478

22.11.22RSSForm 4 59478

21.11.22PR NewswireLilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium

16.11.22PR NewswireLilly to Participate in Evercore ISI HealthCONx Conference

14.11.22RSSForm SC TO-T/A 59478

07.11.22PR NewswireLilly to begin rollout of Tempo® Personalized Diabetes Management Platform

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.